Call for Letters of Intent: Translational Impact Research Program | Cycle 2
D2R | DNA to RNA is launching the next round of funding for the Translational Impact Research (TIR) program. This program supports a select few large-scale translational research projects in RNA-based therapeutics which are expected to have a measurable impact on the health of Canadians. Projects must address the D2R Initiative’s strategic priorities and priority disease areas: oncology, rare diseases, infectious diseases, cardiovascular and cardiometabolic diseases.
Applicant Eligibility:
This competition is open to:
-
Principal Investigator (PI): Must be a McGill faculty member (Assistant, Associate, or Full Professor). The PI leads the initiative and coordinates the project.
-
Co-Investigators: Can be McGill faculty or approved faculty from D2R partner institutions (McMaster, UBC, Ottawa, Sherbrooke, IRCM). They actively contribute to project design and execution.
-
Collaborators: Include individuals from academia, industry, government, or community. They do not receive direct D2R funding but provide expertise, resources, or access relevant to the project.
How to apply:
Letters of Intent (LOIs) are submitted via an online form. LOIs are accepted until Tuesday, October 14, 2025, at 10 a.m. (Eastern Time). Late or incomplete LOIs will not be reviewed.
Funding and duration:
The maximum amount is up to $3,000,000 per project for up to three years (non-renewable).